Recent Company News

• 04:54 AM ET Jun 14, 2026
  

  Eli Lilly presents results from BRUIN CLL-322 clinical trial of Jaypirca ($1133.00, 0.00)

• 11:05 PM ET May 14, 2026
  

  Nippon Shinyaku reports FY net income attributable ¥29.72B vs guidance 26.30B and FactSet ¥27.58B [6 est, ¥26.60-29.70B] (¥4200.0000, +83)

• 11:24 PM ET May 09, 2026
  

  Nippon Shinyaku downgraded to neutral from overweight at JPMorgan

• 05:06 PM ET May 07, 2026
  

  Capricor Therapeutics files lawsuit related to Commercialization and Distribution Agreement with Nippon Shinyaku - 8-K ($33.94, 0.00)

• 09:03 AM ET Apr 22, 2026
  

  Capricor announces late-breaking presentation of HOPE-3 Phase 3 results at the AAN 2026 Annual Meeting ($35.34, 0.00)

• 01:02 AM ET Apr 21, 2026
  

  FDA accepts application for Genentech's Gazyva for the treatment of the most common form of Lupus (CHF 320.90, 0.00)

• 06:48 AM ET Apr 13, 2026
  

  Eli Lilly reports Phase 3 BRUIN CLL-322 trial of Jaypirca combination in r/r CLL/SLL met primary endpoint ($939.47, 0.00)

• 11:04 PM ET Mar 23, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 09:18 PM ET Mar 17, 2026
  

  Nippon Shinyaku launches ELZONRIS injection for treatment of blastic plasmacytoid dendritic cell neoplasm in Japan (¥5188.0000, -54)

• 09:28 AM ET Mar 10, 2026
  

  Capricor Therapeutics announces new PDUFA date for Deramiocel BLA as 22-Aug-26